SGLT2 inhibitor 'promising for type 2 diabetes in children, teens'

The adjunctive oral treatment may be an option for young people, for whom approved agents are limited, researchers say

Oral dapagliflozin may be a useful add-on therapy in youth-onset type 2 diabetes but compliance is a problem, a small phase III study suggests.

The AstraZeneca-funded study failed to meet its primary endpoint of reduced HbA1c concentration but in a pre-specified subgroup of patients who adhered to the therapy there was a significant difference for the SGLT2 inhibitor compared with placebo.

The results suggest dapagliflozin is the first oral glucose-lowering agent since metformin shown to be